Target intelligence / Profile preview

Sigma non-opioid intracellular receptor 1 (SIGMAR1) (SIGMAR1)

Target
SIGMAR1
Molecular classification
Receptor, Other
01

Overview

The Sigma non-opioid intracellular receptor 1 (Sigma-1 receptor, SIGMAR1) is a unique, ligand-regulated transmembrane chaperone protein primarily localized at the mitochondria-associated endoplasmic reticulum membrane (MAM). It plays a critical role in maintaining cellular homeostasis by modulating calcium signaling, endoplasmic reticulum (ER) stress responses, lipid transport, and the trafficking and activity of various ion channels and G-protein-coupled receptors. Originally misclassified as an opioid receptor, the Sigma-1 receptor is now recognized as a distinct, highly conserved protein with no sequence homology to other mammalian receptors. It is widely expressed in the central nervous system, where it is implicated in neuroprotection, synaptic plasticity, and cell survival.

Dysfunction of the Sigma-1 receptor is associated with several neurodegenerative and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), neuropathic pain, depression, and drug addiction. It is also implicated in cancer cell proliferation. The receptor is highly sensitive to various exogenous ligands, with haloperidol acting as a classic high-affinity antagonist. Therapeutic strategies targeting the Sigma-1 receptor include agonists like pridopidine and blarcamesine, which aim to enhance neuroprotection and restore neuronal homeostasis, as well as antagonists like E-52862 (S1RA), which are developed for pain management and the potentiation of opioid analgesia.

Other names
Haloperidol-sensitive sigma siteHaloperidol-sensitive sigma receptorSigma-1 receptorSigma 1 receptorSig-1RS1ROPRS1SR-BPSR-BP1SRBPhSigmaR1sigma1RDSMA2ALS16FTDALS2
02

Mechanism of action

Sigma-1 receptor agonism (which enhances chaperone activity, restores calcium homeostasis, and promotes neuroprotection) and Sigma-1 receptor antagonism (which blocks chaperone activity, modulates neurotransmitter release, and alleviates neuropathic pain).

03

Biological functions

Signal transductionApoptosisOther
04

Disease associations

Neurodegenerative diseaseCancerOther
05

Safety considerations

CNS side effects (e.g., headache, dizziness, euphoria)Potential for drug-induced parkinsonism or worsening of motor symptoms with certain agonistsBiphasic dose-response curve (therapeutic window challenges)Off-target interactions due to ligand promiscuity
06

Interacting drugs

14 more in the full profile.

07

Biomarkers

Sigma-1 receptor occupancy (PET imaging)11C-SA4503 PET18F-fluspidine PETEEG biomarkers of cortical activity

Beyond the preview

Go deeper on Sigma non-opioid intracellular receptor 1 (SIGMAR1) (SIGMAR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sigma non-opioid intracellular receptor 1 (SIGMAR1) (SIGMAR1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call